Crown Bioscience, Inc. has acquired Molecular Response’s PDX models and PDX service operations, expanding its translational oncology services.   Crown gains Molecular Response’s existing PDX models as well as 8,000 viable human tumors for model development, with the ability to further select and develop models from a wider collection. The majority of these tissues come from patients who have received prior treatment, many from metastatic tumors. Each tumor is supported by a companion molecular b...